Related Experiment Videos
Levetiracetam in refractory epilepsy: a prospective observational study
Rajiv Mohanraj1, Pamela G Parker, Linda J Stephen
1Epilepsy Unit, Division of Cardiovascular & Medical Sciences, Western Infirmary, Glasgow, Scotland, UK.
Seizure
|January 12, 2005
Summary
Levetiracetam (LEV) is an effective adjunctive treatment for refractory epilepsy. Many patients achieved seizure freedom or responded well to LEV, often at 1000 mg daily or less.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Refractory epilepsy presents significant treatment challenges.
- Adjunctive therapies are crucial for managing uncontrolled seizures.
Purpose of the Study:
- To evaluate the effectiveness of levetiracetam (LEV) as an adjunctive treatment in patients with refractory epilepsy in a real-world clinical setting.
- To explore optimal dosing strategies for LEV in this patient population.
Main Methods:
- Prospective, open-label study involving 156 patients with refractory localisation-related or idiopathic-generalised epilepsy.
- Flexible dosing schedules of levetiracetam were employed.
- Primary endpoints included seizure freedom, responder status (≥50% reduction), or treatment discontinuation.
Main Results:
- 40% (26%) of patients achieved seizure freedom, with 40% of those with idiopathic-generalised epilepsy becoming seizure-free.
- 63% of seizure-free patients were on 1000 mg of LEV or less daily.
- An additional 21% of patients were responders.
- Levetiracetam was withdrawn in 29% of patients due to adverse effects (17%), lack of efficacy (5%), or both (7%).
- Sedation and behavioral side effects were the most common reasons for discontinuation.
Conclusions:
- Levetiracetam demonstrates efficacy as an adjunctive therapy for refractory epilepsy.
- Optimal response to levetiracetam can often be achieved at doses of 1000 mg per day or less.
- Levetiracetam is a viable treatment option for patients with difficult-to-control epilepsy, though side effects require monitoring.